LAPATINIB in English translation

• lapatinib

Examples of using Lapatinib in Danish and their translations into English

Lapatinib bevarede betydelig aktivitet over for brystcancercellelinjer selekteret for langtidsvækst i trastuzumab- holdigt medium in vitro.
Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro.

Ugers intervaller under behandling med lapatinib for at sikre, det ikke faldt til under institutionens nedre normalgrænse.
In clinical trials LVEF was monitored at approximately eight week intervals during treatment with lapatinib to ensure it did not decline to below the institutions lower limit of normal.

Hvis du er overfølsom(allergisk) over for lapatinib eller et af de øvrige indholdsstoffer i Tyverb.
If you are allergic(hypersensitive) to lapatinib or any of the other ingredients of Tyverb.

undgå at blive gravide under behandlingen med lapatinib.
avoid becoming pregnant while receiving treatment with lapatinib.

Indgift af lapatinib samtidig med moderate inhibitorer af CYP3A4 bør ske med forsigtighed,
Coadministration of lapatinib with moderate inhibitors of CYP3A4 should proceed with caution

Det kan derfor ikke forventes, at hæmodialyse vil være en effektiv måde at øge udskillelsen af lapatinib.
Lapatinib is not significantly renally excreted and is highly bound to plasma proteins, therefore haemodialysis would not be expected to be an effective method to enhance the elimination of lapatinib.

In vitro- forsøg indikerer, at lapatinib er et substrat for transportørerne BCRP(ABCG1)
In vitro studies indicate that lapatinib is a substrate for the transporters BCRP(ABCG1)

Tyverb bør ikke anvendes til patienter, der kan være overfølsomme(allergiske) over for lapatinib eller andre af indholdsstofferne.
Tyverb should not be used in people who may be hypersensitive(allergic) to lapatinib or any of the other ingredients.

Indgift af lapatinib til patienter med moderat til svært nedsat leverfunktion bør ske med forsigtighed pga. øget optagelse af lægemidlet.
Administration of lapatinib to patients with moderate to severe hepatic impairment should be undertaken with caution due to increased exposure to the medicinal product.

blev bedre i mere end 60% af tilfældene ved ophør af behandlingen med lapatinib.
improved in more than 60% of cases on discontinuation of treatment with lapatinib.

Indgift af lapatinib samtidig med kendte induktorer af CYP3A4(fx rifampicin,
Coadministration of lapatinib with known inducers of CYP3A4(e. g. rifampicin,

Effekten og sikkerheden ved lapatinib i kombination med capecitabine til brystcancerpatienter med god performance status blev evalueret i et randomiseret fase III- forsøg.
The efficacy and safety of lapatinib in combination with capecitabine in breast cancer patients with good performance status was evaluated in a randomized, phase III trial.

Indgift af lapatinib samtidig med stærke inhibitorer af CYP3A4(fx ritonavir,
Coadministration of lapatinib with strong inhibitors of CYP3A4(e. g. ritonavir,

Men daglig dosis af lapatinib resulterer i steady state i løbet af 6- 7 dage,
However, daily dosing of lapatinib results in achievement of steady state within 6 to 7 days,

Desuden er følgende bivirkninger blevet associeret med lapatinib i kombination med capecitabine,
In addition, the following adverse reactions were reported to be associated with lapatinib in combination with capecitabine

Lapatinib hæmmer CYP3A(Ki 0, 6- 2, 3 µg/ ml) og CYP2C8(0, 3 µg/ ml)
Lapatinib inhibits CYP3A(Ki 0.6 to 2.3 µg/ ml)

denne havde den samme forekomst i begge grupper lapatinib plus capecitabine.
this had a similar incidence in both treatment groups lapatinib plus capecitabine.

LVEF skal evalueres hos alle patienter før initiering af behandling med lapatinib for at sikre, at patienten har en baseline- LVEF, der ligger inden for institutionens.
LVEF should be evaluated in all patients prior to initiation of treatment with lapatinib to ensure that the patient has a baseline LVEF that is within the institutions normal limits.

undervejs i behandlingen med lapatinib plus capecitabine var gastro- intestinale(diarre,
during therapy with lapatinib plus capecitabine were gastrointestinal(diarrhoea,

initiering af behandling med lapatinib for at sikre, at baseline- LVEF lå inden for institutionens normale grænser.
prior to initiation of treatment with lapatinib to ensure baseline LVEF was within the institutions normal limits.